What is Mallinckrodt Debt-to-Equity?
Mallinckrodt's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $377 Mil. Mallinckrodt's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0 Mil. Mallinckrodt's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-1,098 Mil.
Mallinckrodt's debt to equity for the quarter that ended in Sep. 2023 was -0.34.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Mallinckrodt's Debt-to-Equity or its related term are showing as below:
MCKPF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.34 Med: 1.55 Max: 7.13
Current: -0.34
During the past 12 years, the highest Debt-to-Equity Ratio of Mallinckrodt was 7.13. The lowest was -0.34. And the median was 1.55.
Mallinckrodt Debt-to-Equity Historical Data
The historical data trend for Mallinckrodt's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mallinckrodt Debt-to-Equity Chart
|
Mallinckrodt Annual Data
|
|
Trend |
Sep13 |
Sep14 |
Sep15 |
Sep16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
2.11 |
2.77 |
3.52 |
4.43 |
1.90 |
|
Mallinckrodt Quarterly Data
|
|
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
1.67 |
1.90 |
2.26 |
4.96 |
-0.34 |
Competitive Comparison of Mallinckrodt's Debt-to-Equity
For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mallinckrodt's Debt-to-Equity Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Mallinckrodt's Debt-to-Equity falls into.
Mallinckrodt Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Mallinckrodt's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as
Mallinckrodt's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mallinckrodt (Mallinckrodt) Business Description
Traded in Other Exchanges
N/A
Address
College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Executives
| Alta Fundamental Advisers Llc |
10 percent owner |
1500 BROADWAY, SUITE 704, NEW YORK NY 10036 |
| Jason Daniel Goodson |
officer: EVP & Head of Corp Development |
106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885 |
| James R Sulat |
director |
|
| Paul Bisaro |
director |
|
| Sigurdur O Olafsson |
director, officer: President and CEO |
360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960 |
| Stephen Andrew Welch |
officer: EVP & Head of Spec Generics |
18440 BRIDGEMORE LANE, LOUISVILLE KY 40245 |
| Peter C Richardson |
officer: EVP & Chief Scientific Officer |
28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
| Susan Michele Silbermann |
director |
C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540 |
| Lisa French |
officer: EVP & Chief Commercial Officer |
301 CONTINENTAL LANE, PAOLI PA 19301 |
| Mark Anthony Tyndall |
officer: EVP & Chief Legal Offi & Secre |
1101 Q ST NW, WASHINGTON DC 20009 |
| Henriette Nielsen |
officer: EVP & Chief Transformation OFC |
202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024 |
| Karen Ling |
director |
C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022 |
| Anne Clem Whitaker |
director |
109 BRIERY BRANCH COURT, MORRISVILLE NC 27560 |
| Olifant Luxco S.a R.l. |
10 percent owner |
19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273 |
| Paul Rutherford Carter |
director |
SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF |
Mallinckrodt (Mallinckrodt) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MCKPF has been successfully added to your